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Introduction: Glucose has been deemed the driving force of tumor growth for decades. However, research has
shown that several tumors metabolically shift towards glutaminolysis. The development of radiolabeled gluta-
mine derivatives could be a useful molecular imaging tool for visualizing these tumors. We elaborated on the
glutamine-derived PET tracers by developing two novel probes, namely [18F]fluorophenylglutamine and [18F]
fluorobiphenylglutamine.
Materials andmethods: Both tracers were labelledwith fluorine-18 using our recently reported ruthenium-based
direct aromatic fluorination method. Their affinity was evaluated with a [3H]glutamine inhibition experiment in
a human PC-3 and a rat F98 cell line. The imaging potential of [18F]fluorophenylglutamine and [18F]
fluorobiphenylglutamine was tested using a mouse PC-3 and a rat F98 tumor model.
Results: The radiosynthesis of both tracers was successful with overall non-decay corrected yields of 18.46 ±
4.18% (n = 10) ([18F]fluorophenylglutamine) and 8.05 ± 3.25% (n = 5) ([18F]fluorobiphenylglutamine). In
vitro inhibition experiments showed a moderate and low affinity of fluorophenylglutamine and
fluorobiphenylglutamine, respectively, towards the humanASCT-2 transporter. Both compounds had a low affin-
ity towards the rat ASCT-2 transporter. These results were endorsed by the in vivo experiments with low uptake
of both tracers in the F98 rat xenograft, low uptake of [18F]FBPG in the mice PC-3 xenograft and a moderate up-
take of [18F]FPG in the PC-3 tumors.
Conclusion:We investigated the imaging potential of two novel PET radiotracers [18F]FPG and [18F]FBPG. [18F]FPG
is the first example of a glutamine radiotracer derivatized with a phenyl group which enables the exploration of
further derivatization of the phenyl group to increase the affinity and imaging qualities. We hypothesize that in-
creasing the affinity of [18F]FPG by optimizing the substituents of the arene ring can result in a high-quality
glutamine-based PET radiotracer.
Advances in Knowledge and Implications for patient care:We hereby report novel glutamine-based PET-tracers.
These tracers are taggedon the arene groupwithfluorine-18, herebypreventing in vivo defluorination,which can
occur with alkyl labelled tracers (e.g. (2S,4R)4-[18F]fluoroglutamine). [18F]FPG shows clear tumor uptake in vivo,
has no in vivo defluorination and has a straightforward production.We believe this tracer is a good starting point
for the development of a high-quality tracer which is useful for the clinical visualization of the glutamine
transport.
© 2020 Elsevier Inc. All rights reserved.60, 9000 Gent, Belgium.
of Chemistry and Biochemistry,
, beyzavi@uark.edu1. Introduction
The introduction of nuclear medicine in clinical practice has shifted
the use of imaging in oncology. While magnetic resonance imaging
(MRI) and computed tomography (CT) visualize tumor anatomy, the ad-
dition of nuclear medicine provides a more functional understanding.
Positron emission tomography (PET) is a nuclear medicine technique
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hallmarks in cancer, making it possible to visualize what is happening on
a molecular level [1–3]. A successful example of such a PET radiotracer is
[18F]fluorodeoxyglucose ([18F]FDG). Ever since its Federal Drug Agency
(FDA) approval in 1996, [18F]FDGhas been the golden standard in nuclear
medicine imaging in oncology. Due to the high sensitivity, the application
of [18F]FDG PET has proven to be useful, for example, in staging and ther-
apy response assessment [2–4]. Nevertheless, [18F]FDG is of limited value
for tumors with high background uptake (e.g. brain tumors), low tumor
uptake (e.g.neuroendocrine tumors, prostate cancer, hepatocellular carci-
noma) or in the presence of tumor-associated inflammation [5–8].
Amino acids also show increased uptake in malignant cells and seem
to overcome several of the glucose-related limitations. Several
radiolabeled amino acids targeting the L-type amino acid transporter 1
(LAT1) such as O-(2-18F-fluoroethyl)-L-tyrosine ([18F]FET), (S-11C-
methyl)-L-methionine ([11C]MET) and 3,4-dihydroxy-6-18F-fluoro-L-
phenylalanine ([18F]FDOPA) show favorable tumor visualization and
are already used in clinical practice [5–8]. Another amino acid that
draws attention in cancer metabolism is glutamine [9]. Being the most
abundant amino acid in blood and muscle, glutamine is also an essential
amino acid formalignant cells as several tumors seem to beunable to sur-
vivewithout the presence of exogenous glutamine. It is both a carbon and
nitrogen source and participates in the cellular redox homeostasis, which
explains the “glutamine addiction” [10–13]. Some tumors have even
been reported to metabolically shift to glutaminolysis, resulting in nega-
tive [18F]FDG PET scans [14,15]. All these aspects led to the development
of glutamine-based PET tracers e.g. [11C]glutamine, (2S,4R)4-[18F]
fluoroglutamine, (2S,4S)4-(3-[18F]fluoropropyl)glutamine and (2S,4S)
2,5-diamino-4-(4-(2-[18F]fluoroethoxy)benzyl)-5-oxopentanoic acid
[16–20]. As an isotopic variant, [11C]glutamine has identical physico-
chemical properties to normal glutamine. However, due to its short
half-life (t1/2 = 20.3 min) and difficult radiochemical synthesis, no
human clinical studies have yet been performed [17,20]. To address the
short half-life, a fluorine-18 analogue was developed: (2S,4R)4-[18F]
fluoroglutamine. Unfortunately, the fluorine-18 derivative of glutamine
shows in vivo defluorination and its synthesis is complex with different
stereoisomers being formed [18,20,21]. (2S,4S)4-(3-[18F]-fluoropropyl)
glutamine is more stable in vivo, but suffers low labelling yields and
shows system L preference. (2S,4S)2,5-diamino-4-(4-(2-[18F]-
fluoroethoxy)benzyl)-5-oxopentanoic acid shows much lower uptake
in vitro and was not yet evaluated in vivo [19,20].
In this study, we further elaborated on the glutamine-derived PET-
tracers. Therefore, we aimed to obtain fluorine-18 labelled inhibitors of
the alanine-serine-cysteine transporter-2 (ASCT-2), one of the most im-
portant transporters of glutamine. The first radiotracer we synthesized
was the fluorine-18 variant of the known inhibitor L-γ-glutamyl-p-
nitroanilide (GPNA) [22]. For the second radiotracer we decided to ex-
pand the aromatic system of GPNA to a biphenyl group. As such, we
aimed at a better affinity for the ASCT-2 transporter by better filling the
hydrophilic pocket described in different homology models [22–24].
The organic synthesis of both precursors and cold reference products
was based on a method described by Schulte et al. [23]. In order to
avoid interference with the glutamine backbone, implementation of the
radioisotope was performed directly at the aromatic rings. Therefore,
we attempted to develop the fluorine-18 labelled derivative of glutamine
via a ruthenium-based direct aromatic fluorination method [25]. Both
tracers were evaluated in vitro for their affinity towards the ASCT-2. Fi-
nally, as a proof of concept, PET-images were acquired in a mouse
model for prostate cancer and a rat model for glioblastoma.
2. Materials & methods
2.1. General
All reactions describedwere performed under nitrogen atmosphere.
Chemicals were at least reagent grade, obtained from Sigma Aldrich(Bornem, Belgium), TCI Europe (Zwijndrecht, Belgium), Activate Scien-
tific (Prien, Germany), Acros (Geel, Belgium) or ChemCollect (Wupper-
tal, Germany) and used as received. All solvents were obtained from
Chemlab (Zedelgem, Belgium) and were at least HPLC-grade. Pre-
coated TLC sheets ALUGRAM® Xtra SIL G/UV254 were used to monitor
reactions under 254 nm UV-light. Staining of TLC was performed by
spraying with either basic aqueous solution of KMnO4 (1.0 g KMnO4,
2.0 g K2CO3, 100 mL H2O) or ninhydrin (1.5 g ninhydrin, 3.0 mL acetic
acid, 100 mL EtOH) solution and subsequent charring. Purification was
performed with silica column chromatography either manually with
Machery-Nagel Kieselgel 60 (63–200 μm) or on a Reveleris X2 (Grace)
automatic system and accessory pre-packed silica columns. A Waters
LCT Premier XE Time of Flight (TOF) mass spectrometer equipped
with electrospray ionization (ESI) and a modular Lockspray™ interface
was used to obtain high resolution mass spectra. NMR spectra were re-
corded with a Varian Mercury-300BB (300/75 MHz) spectrometer.
2.2. Chemistry
2.2.1. General procedure A (amine acylation of aniline with protected
glutamate)
To a heat-dried flask containing the Boc-L-Glu-OtBu (500 mg,
1.65 mmol, 1.00 eq), aniline (1.65 mmol, 1.00 eq), 1-[Bis
(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-
oxid hexafluorophosphate (HATU) (627 mg, 1.65 mmol, 1.00 eq),
diisopropylethylamine (DIPEA) (0.57 mL, 3.30 mmol, 2.00 eq) and a
magnetic stirring bar under N2 gas was added anhydrous DMF (18 mL,
11 mL/mmol) as a solvent. The reaction mixture was stirred overnight
at 120 °C. The next day the solution was cooled to room temperature
and DMF was evaporated in vacuo. Next, the mixture was partitioned
in water/CH2Cl2, and extracted with CH2Cl2 (2×). The organic layer
was dried by passing it over a Büchner funnel filled with sodium sul-
phate. The filtrate was absorbed onto celite®, concentrated in vacuo
and purified by flash chromatography on silica gel (hexane:ethyl
acetate).
2.2.2. General procedure B (cleavage of tert-butyl and N-boc protection
groups)
The purified compounds were dissolved in 4.0 M HCl in dioxane
(10 mL/mmol) in an anhydrous environment and were stirred 4 h at




Boc-L-Glu-OtBu (500 mg, 1.65 mmol) and 4-fluoroaniline (183 mg,
1.65 mmol) were coupled using general procedure A. The mixture,
absorbed onto celite®, was purified using automated flash chromatog-
raphy (12→ 25% EtOAc in hexane) to afford 1 (503 mg, 1.27 mmol) as
a white powder in 77% yield. Rf 0.35 (25% EtOAc/75% Hex). 1H NMR
(300 MHz, CDCl3): δ 1.45 (d, J = 3.0 Hz, 18H, tBu), 1.74–1.94 (m, 1H,
CH2-CH2-CH), 2.18–2.32 (m, 1H, CH2-CH2-CH), 2.36–2.48 (m, 2H, NH-
OC-CH2-CH2), 4.14–4.28 (m, 1H, CH-NH), 5.36 (d, J = 7.7 Hz,1H, NH-
tBu), 6.95–7.04 (m, 2H, HPhe), 7.57 (dd, J = 4.8 Hz and 3.8 Hz, 2H,
HPhe), 8.93 (s, 1H, PhNH). 13C NMR (75 MHz, CDCl3): δ 27.96, 28.30,
30.69, 34.02, 53.19, 80.55, 82.79, 115.29, 115.58, 121.31, 134.54,
156.65, 157.52, 160.74, 170.48, 171.22. 19F NMR (282 MHz, DMSO‑d6):
δ [−119.69; −119.56] (m). Exact Mass: (ESI-MS) for C20H30FN2O5
[M+ H] found, 397.2161; calcd, 397.2139.
2.2.4. tert-Butyl N2-(tert-butoxycarbonyl)-N5-(4-hydroxyphenyl)
glutaminate (2)
Boc-L-Glu-OtBu (500 mg, 1.65 mmol) and 4-aminophenol (180 mg,
1.65 mmol) were coupled using general procedure A. The mixture,
absorbed onto celite®, was purified using automated flash chromatog-
raphy (25→ 50% EtOAc in hexane) to afford 2 (382 mg, 0.97 mmol) as
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NMR (300 MHz, CDCl3): δ 1.44(s, 18H, tBu), 1.81–1.98 (m, 1H, CH2-
CH2-CH), 2.15–2.29 (m, 1H, CH2-CH2-CH), 2.40 (t, J = 7.0 Hz, 2H, O=
C-CH2-CH2), 2.81(s, 1H, OHPhe), 4.07–4.25 (m, 1H, CH-NH), 5.38 (d,
J = 8.0 Hz, 1H, NH-tBu), 6.78(d, J = 8.7 Hz, 2H, HPhe), 7.36(d, J =
8.5 Hz, 2H, HPhe), 8.55(s,1H, PhNH). 13C NMR (75 MHz, CDCl3): δ
27.95, 28.30, 30.21, 33.81, 53.41, 80.50, 82.72, 115.63, 122.16, 130.58,
153.26, 156.49, 170.75, 171.33. Exact Mass: (ESI-MS) for C20H31N2O6
[M+ H] found, 395.2174; calcd, 395.2182.
2.2.5. tert-Butyl N2-(tert-butoxycarbonyl)-N5-(4′-fluoro-[1,1′-biphenyl]-
4-yl)glutaminate (3)
Boc-L-Glu-OtBu (500 mg, 1.65 mmol) and 4′-fluoro-[1,1′-biphenyl]-
4-amine (309mg, 1.65mmol) were coupled using general procedure A.
The mixture, absorbed onto celite®, was purified using manual flash
chromatography (15 → 30% EtOAc in hexane) to afford 3 (577 mg,
1.22 mmol) as a white powder in 74% yield. Rf 0.19 (25% EtOAc/75%
Hex). 1H NMR (300 MHz, CDCl3): δ 1.47 (d, J = 6.0 Hz, 18H, tBu),
1.79–1.95 (m, 1H, CH2-CH2-CH), 2.21–2.36 (m, 1H, CH2-CH2-CH), 2.46
(t, J = 7.3 Hz, 2H, O=C-CH2-CH2), 4.17–4.30 (m, 1H, CH-NH), 5.37(d,
J = 8.0 Hz, 1H, NH-tBu), 7.06–7.15 (m, 2H, HPhe), 7.47–7.56 (m, 4H,
HPhe), 7.69 (d, J = 8.4 Hz, 2H, HPhe), 8.96 (s,1H, PhNH). 13C NMR
(75 MHz, CDCl3): δ 27.98, 28.31, 30.80, 34.19, 53.21, 80.56, 82.80,
115.43, 115.72, 120.06, 127.38, 128.27, 128.37, 135.84, 136.79, 137.77,
156.65, 160.64, 163.91, 170.52, 171.25. 19F NMR (300 MHz, CDCl3): δ:




Boc-L-Glu-OtBu (500mg, 1.65mmol) and 4′-amino-[1,1′-biphenyl]-
4-ol (305mg, 1.65mmol) were coupled using general procedure A. The
mixture, absorbed onto celite®, was purified using automated flash
chromatography (20 → 50% EtOAc in hexane) to afford 4 (442 mg,
0.94 mmol) as a white powder in 57% yield. Rf 0.37 (50% EtOAc/50%
Hex). 1H NMR (300 MHz, DMSO‑d6): δ 1.38 (d, J = 5.7 Hz, 18H, tBu),
1.72–1.88 (m, 1H, CH2-CH2-CH), 1.92–2.07 (m, 1H, CH2-CH2-CH), 2.38
(t, J = 7.5 Hz, 2H, O=C-CH2-CH2), 3.72–3.89 (m, 1H, CH-NH),
6.70–6.84 (m, 2H, HPhe), 7.13 (d, J = 7.8 Hz, 1H, HPhe), 7.39–7.51 (m,
3H, HPhe), 7.57–7.63 (m, 2H, HPhe), 9.45 (s, 1H, PhNH), 9.94 (s, 1H,
PhOH). 13C NMR (75 MHz, DMSO‑d6) δ 26.68, 28.10, 28.63, 33.12,
54.36, 78.52, 80.78, 116.10, 119.80, 126.48, 127.16, 127.70, 131.02,
135.30, 138.21, 155.99, 157.18, 170.67, 172.08. Exact Mass: (ESI-MS)
for C26H35N2O6 [M + H] found, 471.2487; calcd, 471.2495.
2.2.7. N5-(4-fluorophenyl)glutamine (5)
The tert-butyl and N-boc protection groups of compound 1 were re-
moved using general procedure B, to obtain compound 5, a white pow-
der, in quantitative yields. 1H NMR (300 MHz, DMSO‑d6): δ 2.00–2.15
(m, 2H, CH2-CH2-CH), 2.51–2.65 (m, 2H, O=C-CH2-CH2), 3.80 (t, J =
6.2 Hz, 1H, CH-NH2), 7.10 (t, J = 8.9 Hz, 2H, HPhe), 7.61 (dd, J =
9.0 Hz and 5.1 Hz, 2H, HPhe), 10.35 (s, 1H, PhNH). 13C NMR (75 MHz,
DMSO‑d6): δ 26.39, 32.16, 52.10, 115.45, 115.74, 121.15 (m), 136.03
(m), 156.71, 159.88, 170.25, 170.38, 171.18. 19F NMR (282 MHz,
DMSO-D6): δ [−119.70; −119.56] (m). Exact Mass: (ESI-MS) for
C11H14FN2O3 [M+ H] found, 241.0987; calcd, 241.0988.
2.2.8. N5-(4′-fluoro-[1,1′-biphenyl]-4-yl)glutamine (6)
The tert-butyl and N-boc protection groups of compound 3were re-
moved using general procedure B, to obtain compound 6, a white pow-
der, with quantitative yields. 1H NMR (300 MHz, TFA-d): δ 2.47–2.88
(m, 2H, CH2-CH2-CH), 3.07–3.23 (m, 2H, O=C-CH2-CH2), 4.58–4.76
(m, 1H, CH-NH2), 7.09–7.78(m, 8H, HPhe). 13C NMR (75 MHz, TFA-D):
δ 24.77, 32.13, 53.59, 66.25, 114.87, 115.16, 123.78, 127.48, 128.33 (d,
J = 8 Hz), 132.57, 135.99 (d, J = 3 Hz), 140.63, 164.31, 172.54,
174.70. 19F NMR (300 MHz, DMSO‑d6): δ [−116.24; −116.10] (m).Exact Mass: (ESI-MS) for C17H18FN2O3 [M + H] found, 317.1297;
calcd, 317.1301.
2.3. Radiochemical synthesis of [18F]fluorphenylglutamine ([18F]FPG) and
[18F]fluorbiphenylglutamine ([18F]FBPG)
The chemical labelling of compounds 2 and 4 with fluorine-18 was
done via an aromatic fluorination method described by Beyzavi et al.
[25]. The fluoride used for these reactions was produced in a cyclone
18/9 cyclotron (IBA) with a 18O(p,n) nuclear reaction. The [18F−]
(2.2 GBq) obtained in an aqueous solution was trapped on a HCO3−
SPE column and washed with 1.0 mL extra dry acetonitrile. A mixture
of precursor (3.0 mg), CpRu(COD)Cl (5.0 mg) and N,N′-bis(2,6-
diisopropylphenyl)-2-chloroimidazolium chloride) (18.0 mg) was
used to elute the fluoride from the SPE column in a 5.0 mL borosilicate
vial. Extra dry DMSO (150 μL) and MeCN:DMSO (50:50, 50 μL) was
used to flush the remaining fluoride. The resulting mixture was heated
to 125 °C for 30 min.
Upon completion of the reaction, the vialwas cooled in an ice bath to
room temperature. After cooling down themixturewas dilutedwith ul-
trapure water (4.5 mL) and trapped on a Sep-Pak C18 cartridge
(preconditioned with MeCN (10.0 mL) and ultrapure water
(10.0 mL)). The cartridge was washed with ultrapure water (10.0 mL),
flushed twice with air and eluted with extra dry MeCN (1.0 mL). The
MeCN was evaporated under a gentle stream of nitrogen at 125 °C.
After evaporation of the solvent, the vial was cooled to room tempera-
ture. The protecting groupswere removed by adding 4MHCl in dioxane
(200 μL) and heating the vial for 3.5min to 90 °C. After cooling down the
mixture, mobile phase (300 μL) was added to neutralize the pH. Purifi-
cation was then done by injecting onto HPLC using a C18 prep column
(Atlantis T3 OBD prep column, 100 Å, 10 μM, 10 mm × 250 mm, 1/
pkg., Waters). Elution of the desired radiotracer was followed with a
radiodetector (Ludlum Measurements Inc) coupled to the HPLC. [18F]
FPG eluted after approximately 12 min (mobile phase ethanol/ammo-
nium acetate (10 mM) in ultrapure water 10:90 (V:V); flowrate 6 mL/
min) and was used as such. [18F]FBPG eluted after approximately
16 min (mobile phase ethanol/ammonium acetate (10 mM) in ultra-
pure water 30:70 (V:V); flowrate 6 mL/min) and was diluted with PBS
before further usage.
Quality control of the obtained radiotracerwas done bymeans of an-
alytical HPLC with radio- and UV detection (205 nm; Waters) using a
1.0mL/min flow and aGrace Alltima C18 (4.6 × 250mm; 5 μm) column.
The retention times of the fluorine-18 labelled compounds were com-
pared to the retention time of the fluorine-19 reference compounds.
[18F]FPG was compared to [19F]FPG (retention time 8.53 min) in an
isocratic run using ethanol/ammonium acetate (10 mM) in ultrapure
water 10:90 (V:V). [18F]FBPG was compared to [19F]FBPG (retention
time 10.35 min) in an isocratic run using ethanol/ammonium acetate
(10 mM) in ultrapure water 30:70 (V:V). The LogD7.4 of both tracers
were determined by adding 1 MBq of respectively [18F]FPG and [18F]
FBPG to a mixture of PBS water and n-octanol (1:1; V:V). Samples
were vortexed and centrifuged (10 min; 1100 g) where after aliquots
were taken from each layer whichweremeasured in a NaI (Tl) scintilla-
tion counter (Capintec; Ramsey, NJ, USA). LogD7.4 was calculated as the
logarithm of the proportion of counts in the octanol and PBS layers.
2.4. In vitro experiments
2.4.1. General information
The PC-3, F98 and wild-type HEK-293 cell lines were purchased
from ATCC and the SLC1A5 knock-out HEK-293 cell line from Creative
Biogene. The PC-3 cell line was cultivated in RPMI medium enriched
with 10% fetal calf serum, 1% L-glutamine and penicillin/streptomycin
(50 U/mL). The F98, wild-type HEK-293 and SLC1A5 knock-out HEK-
293 cell line were cultivated in Dulbecco's modified Eagle's medium
(DMEM) enriched with 10% fetal calf serum, 1% L-glutamine and
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bator set to 37 °C and 5% CO2 environment. The presence of ASCT-2 ex-
pression in PC-3 and F98 cell lineswas verifiedwithflow cytometry. The
analysis was performed using the LSR II (BD Biosciences) as described
by De Munter et al. [26]. Both cell lines (100,000 cells/100 μL) were
stained at their surface with a primary (rabbit ab; ASCT-2 (V501)) and
secondary antibody (Fab2 (PE Conjugate); anti-rabbit IgG) against
ASCT-2 as a negative control. The cells were fixed and permeabilized
followed by intracellular bindingwith the primary antibody. After bind-
ing of the primary antibody, the secondary antibody was added and
after the incubation period, all samples were analyzed. The ASCT-2
knock-out cell line was engineered with CRISPR-CAS 9 using a HEK-
293 cell line. Absence of ASCT-2 was also explored via flow cytometry.
The percentage of ASCT-2 positive cells was b1%, indicating that the
knock-out efficiency approximates 100%.
Cell tests were performed in 24-well plates (VWR, US). PC-3, F98,
wild-type HEK-293 and SLC1A5 KO HEK-293 cells were seeded the
day prior to the test in a concentration of respectively 175,000;
125,000; 175,000 and 175,000 cells per milliliter. The 24-well plates
used for the cell tests with the wild-type HEK-293 and ASCT-2 knock-
out HEK-293 cell line were coated prior to seeding to achieve good at-
tachment of the cells. To coat the plate 300 μL of Poly-D-lysine stock so-
lution (0.1 mg/mL) was added to each well. The plates were dried for
30 min until all solvent was removed. Upon removal of the solvents
the plates were ready for cell attachment. The [3H]glutamine uptake
studies were performed in HEPES+ buffer (pH 7.4; 100 mM NaCl
(Sigma Aldrich, Belgium), 2 mM KCl (Sigma Aldrich, Belgium), 1 mM
MgCl2 (VWR,US), 1mMCaCl2 (VWR,US), 10mMHepes (SigmaAldrich,
Belgium), 5 mM Tris (VWR, US), 1 g/L glucose (VWR, US) and 1 g/L Bo-
vine Serum Albumin (Sigma Aldrich, Belgium)). A glutamine stock con-
centration (43.8 mg/30 mL HEPES+) was used to make the desired
concentration series. To each stock solution a total of 111 kBq [3H]-L-
glutamine (Perkin Elmer, Massachusetts)/mLwas added. Concentration
series containing the compounds of interest ([19F]FPG and [19F]FBPG)
were made next to the reference glutamine concentration series. At
the start of the experiments, the medium was aspirated, and all wells
were washed twice with HEPES+. After removal of HEPES+, 250 μL
test solution was added, and the plates were incubated for 5 min at
37 °C. Uptake was stopped after 5 min by placing the plates on ice and
adding 1mL ice-cold PBS+ BSA (1 g/100mL). PBS+ BSAwas removed
and the wells were washed twice with 2 mL ice cold PBS. Cells were
lysed by placing the plates on a shaker after adding 250 μL 0.1 M
NaOH (VWR, US). Aliquots of 150 μL were pipetted out of each well
into a scintillation bottle (Perkin Elmer, Massachusetts, USA). To each
scintillation bottle, 5 mL of scintillation cocktail (Ultima Gold, Perking
Elmer, Massachusetts, USA) was added. Samples were measured with
an automated scintillation counter (TriCarb 2900 TR; Perkin Elmer,
Massachusetts, USA). From each plate 25 μL cell lysis was subjected to
the bichoninic acid assay (BCA) (ThermoFisher Scientific) to correct
for protein density.
2.4.2. Concentration dependency
The uptake of [3H]-L-glutamine was tested in F98 rat cells and PC-3
human cells in absence of cold reference product and was compared
to the uptake in the presence of cold reference products. The glutamine
stock solution used ranged from 10 μM to 1200 μM. To data obtained
from the liquid scintillation counter was plotted via non-linear regres-
sion in GraphPad prism v5.01 (GraphPad Software, San Diego, CA,
USA) to obtain Michealis-Menten parameters. Km (values in absence
of cold product) and Km,app (apparent values in presence of cold prod-
uct) data were used to calculate the Ki values according to the formula:
Ki= [I]/((Kmapp/Km)− 1) with [I] being the concentration of inhibitor.
2.4.3. Inhibition of [3H]-labelled amino acid uptake
The inhibition of [3H]-L-serine and [3H]-L-glutamic acid uptake was
evaluated in a PC-3 cell line as a positive and negative control forASCT-2 mediated glutamine inhibition, respectively. The PC-3 cells
were incubated with a [3H]-L-serine/serine solution or [3H]-L-glutamic
acid/glutamic acid (250 μL, 150 μM) for 5 min at 37 °C, in the absence
and presence of all tracers. The serine and glutamic acid inhibition
values were compared to the inhibition of glutamine uptake.
To evaluate the selectivity of the radiotracers, the inhibition of the
[3H]-L-glutamine uptake in absence of ASCT-2 was measured in a
SLC1A5 knock-out cell line. The cells were incubated with 250 μL
50 μM [3H]-L-glutamine/glutamine in the absence and presence of
both tracers for 5 min at 37 °C. The inhibition of glutamine uptake in
SLC1A5 knock-out HEK-293 cells was compared to glutamine inhibition
in ASCT-2 expressing wild-type HEK-293 cells which was evaluated
using the same protocol.
2.4.4. In vitro evaluation of stability in formulation
The stability of [18F]FPG and [18F]FBPGwas evaluated in their formu-
lation. After radiosynthesis, the radiotracer was incubated in its formu-
lation for 30, 70, 120 and 180 min at 37 °C. At the indicated time points
7MBqwas analyzed by the same analytical HPLCmethod used to deter-
mine the purity and identity of [18F]FPG and [18F]FBPG.
2.5. In vivo experiments
All animal experiments were in accordance with the regulations set
up by the Ghent University Ethical Committee andwere approved prior
to the start of the study by the local Ethical Committee on Animal Exper-
iments (ECD 17/08 and ECD 18/21). During housingwater and foodwas
provided ad libitum. Animalswere fastedminimal 6 h prior to PET scans.
Anesthesia was induced with 5.0% isoflurane (V:V in O2) and main-
tained with 2.0% until the end of the experiment. After intravenous in-
jection in the lateral tail vein, 1-hour dynamic PET acquisitions were
performed on a FLEX Triumph II small animal PET/CT-scanner (PET
field of view: 7.5 cm axial; 1.3 mm spatial resolution; TriFoil Imaging).
Upon completion of the PET-scan an additional CT-scan was performed
for anatomical correlation purposes. [18F]FPG and [18F]FBPG uptakewas
evaluated in both PC-3 and F98 tumors. The PET data were obtained in
list mode and reconstructed iteratively (50 iterations) in frames of
1 min the first 25 min and frames of 5 min for the following 35min. Re-
gion of interests (ROI) were drawnmanually around the tumor and tis-
sue for comparison (legmuscle and contralateral brain tissue for the PC-
3 and F98 animal models, respectively). ROI's were converted to stan-
dard uptake values (SUV) following
SUV ¼ Radioactivity in ROI=injected activityð Þ  body weight
with injected activity corrected for radioactive decay and residual radio-
activity in the syringe.
2.5.1. PC-3 xenograft model
At the day of inoculation, the PC-3 cells were harvested and
suspended in non-enriched RPMI medium to obtain a 5 × 107 cells/mL
cell suspension. Male swiss nu/nu mice (n = 5) were inoculated with
5 × 106 PC-3 tumor cells (+0,1 mL Matrigel®) in the right flank at the
age of 8 weeks. One week later the mice were inoculated in the left
flank with 5 × 106 PC-3 tumor cells (+0,1 mL Matrigel®). Tumor
growth was followed with manual caliper measurement. Dynamic
μPET scans were acquired seven weeks post-inoculation after intrave-
nous injection of 18.5MBq radiotracer. PET and CT images were aligned
using the AMIDE (Source Forge Media, La Jolla, CA, USA) software.
Tumor-to-muscle (T/M) ratios were calculated with the leg muscle as
reference region.
2.5.2. Orthotopic F98 model
The F98 glioblastoma rat model was obtained by the same method
described by Verhoeven et al. [27]. A suspension of 20 × 103 F98
tumor cells was injected into the right frontal lobe of female Fischer
Scheme1. Synthesis of precursors for radiolabeling (2 and 4) and cold reference products (5 and6). Reagents and conditions: a) aniline, HATU,DIPEA, DMF, 120 °C, overnight; b)HCl (4M/
dioxane), 40 °C, 4 h.
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contrast-enhanced T1-weighted MRI (7T PharmaScan 70/16, Bruker
BioSpin, Ettlingen, Germany). Upon tumor confirmation on MRI (±
12 days post inoculation), dynamic PET acquisitions were obtained
after injection of 37 MBq radiotracer. Co-registration of the images
was done in PMOD. First, the CT-MRI and CT-PET images were aligned.
Next the MRI images were aligned to the PET images. Tumor tissue
was delineated based on the contrast-enhancing region on T1-
weighted MRI. A reference region (2 × 2 × 2mm3) was delineated con-
tralateral to the tumor.
2.5.3. Biodistribution study
The distribution of the [18F]FPG and [18F]FBPG to thedifferent organs
of PC-3 inoculated mice was evaluated by means of a biodistribution
study. The PC-3 xenograft model was set up as discussed above. Seven
weeks post-inoculation, 5.0 MBq of radiotracer was injected intrave-
nously via the lateral tail vain. At the indicated time points (20 min
and 60 min post-injection) the mice were euthanized by cervical dislo-
cation (n = 3 for each time point). Blood was extracted via cardiac
puncture and the organs were removed during dissection. To avoid
any interference of adhering blood, all organs were rinsed with water.
Subsequent weighing of the samples and counting of the radioactive
signal provided the uptake in the organs expressed as percentage
injected dose per gram of tissue (%ID/g) ± SD.
3. Results
3.1. Chemistry
The synthetic approach for both the precursors and cold reference
products of [18F]fluorophenylglutamine and [18F]
fluorobiphenylglutamine is based on the method described by Schulte
et al. (2015) (Scheme 1) [23]. Formation of the amide was realized by
a HATU based coupling of the aniline to the protected glutamate. Subse-
quent deprotection of 1 and 3with 4MHCl in dioxane provides the cold
reference compounds 5 and 6. Deprotection of 1 and 3 was tested with
aqueous HCl (6M), however, this led to excessive generation of impuri-
ties. The use of 4.0MHCl in dioxane led to pure cold reference products.Scheme 2. Radiochemical synthesis of [18F]FPG and [18F]FBPG. Reagents and conditions: a) Rut
(2,6-diisopropylphenyl)-2-chloroimidazolium chloride, [18F]fluoride, DMSO:MeCN (1:1); b) H3.2. Radiochemistry
3.2.1. [18F]fluorophenylglutamine
[18F]fluorophenylglutamine ([18F]FPG) was synthesized as de-
scribed in Scheme 2 with a non-decay corrected radiochemical yield
of 18.46 ± 4.18% (n = 10) and a total synthesis time of 88 ± 4 min.
Compound verification was performed by means of co-injecting cold
reference product N5-(4-fluorophenyl)glutamine onto analytical HPLC
(tr [18F]FPG=8.8min) (chromatogram see supplementary information
Figs. S1 and S2). Radiochemical purity of [18F]FPG was N99% as deter-
mined by analytical HPLC. The logD7.4 (octanol/PBS ratio at pH7.4)mea-
sured for [18F]FPG was−0.70 ± 0.02 (n= 3).
3.2.2. [18F]fluorobiphenylglutamine
[18F]fluorobiphenylglutamine ([18F]FBPG) was synthesized based
on our recent protocol [25] as described in Scheme 2 with a non-
decay corrected radiochemical yield of 8.05 ± 3.25% (n = 5) and a
total synthesis time of 97 ± 12 min. Compound verification was done
by means of co-injecting cold reference product N5-(4′-fluoro-[1,1′-bi-
phenyl]-4-yl)glutamine onto analytical HPLC (tr [18F]FBPG = 11.1 min)
(chromatogram see supplementary information Fig. S3 and S4). Radio-
chemical purity of [18F]fluorobiphenylglutamine was N99% as deter-
mined by analytical HPLC. The LogD7.4 (octanol/PBS ratio at pH 7.4)
measured for [18F]FBPG was 1.11 ± 0.01 (n = 3).
3.3. In vitro experiments
3.3.1. Flow cytometry
Flow cytometry confirmed the expression of ASCT-2 on both the PC-
3 and F98 cell line (see Fig. 1). The PC-3 cell line showed a median pop-
ulation of 12,056 while the median population of the negative control
was 576. In comparison, the median population in the F98 was 28,585
with a median population of the negative control of 919.
3.3.2. Concentration dependency
Affinity constants Ki were calculated for both compounds and can be
found in Table 1. FPG shows moderate affinity towards the ASCT-2
transporter on the human PC-3 cell line and a low affinity to thehenium complex: CpRu(COD)Cl (Cp: cyclopentadienyl, COD: 1,5-cyclooctadiene, N,N′-bis
Cl (4 M/dioxane).
Fig. 1. FACS analysis of ASCT-2 presence onPC-3 and F98 cells. The top leftfigure represents surface staining (negative control). The top rightfigure is intracellular staining of PC-3 cells. The
bottom left figure is surface staining of F98 cells (negative control). The bottom right figure is intracellular staining of F98 cells.
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the transporter on both PC-3 and F98 cell lines. Michaelis-Menten
plots for glutamine uptake in the presence and absence of the inhibitors
can be found in Fig. 2.
Inhibition of [3H]-labelled amino acid uptake:
The inhibition of the [3H]-L-serine uptake, which is transported
through ASCT-2, serves as a positive control that the developed radio-
tracers target ASCT-2. [19F]FPG and [19F]FBPG inhibit the [3H]-L-serine
uptake, confirming that these compounds interact with ASCT-2
(Table 2). The inhibition of the [3H]-L-glutamic acid uptake, which is
not transported through ASCT-2, serves as a negative control. [19F]FPG
and [19F]FBPG do not inhibit the [3H]-L-glutamic acid uptake, indicating
these compounds do not interact with the glutamic acid transporters.
Table 3 compares the percentual inhibition of [3H]glutamine uptake
between the wild-type HEK-293 and the ASCT-2 knock-out HEK-293
cell line. Glutamine is transported across the cell membrane bymultipleTable 1
Ki values of FPG and FBPG for theASCT-2 transporter on both the PC-3 and F98 cell line. Km
(values in absence of cold product) and Km,app (apparent values in presence of cold prod-
uct) data were used to calculate the Ki values according to the formula: Ki= [I]/((Kmapp/
Km)− 1) with [I] being the concentration of inhibitor.
Compound Ki value PC-3 (μM) Ki value F98 (μM)
FPG 234 850
FBPG 604 1421transporters, after knock-out of ASCT-2 in the HEK 293 cell line, the
other transporter families still preserve their function. Both compounds
inhibit the [3H]glutamine transport in the absence of the ASCT-2 trans-
porter. As such, they inhibit the other glutamine transporting proteins,
indicating that they are not specific for ASCT-2.
3.3.3. In vitro stability
Both [18F]FPG and [18F]FBPG remained stable in their formulation for
at least 3 h. No degradation products were found bymeans of analytical
HPLC.
3.4. In vivo experiments
3.4.1. PC-3 xenograft model
Semi-quantitative values for both radiotracers can be found in
Table 4. [18F]FPG shows moderate tumor uptake in the mice bearing
PC-3 xenografts (see Fig. 3). Only a very low uptake in the PC-3 xeno-
graft was seen for [18F]FBPG (see Fig. 3).
3.4.2. Orthotopic F98 model
Glioblastoma growth in the right frontal lobewas confirmed on both
T2-weighted and contrast-enhanced T1-weighted MRI, two weeks
post-inoculation of F98 cells. Although both radiotracers enter the rat
brain, no accumulation in the tumor was seen (see Fig. 4).
3.5. Semi-quantitative analysis
The acquired PET data of [18F]FPG and [18F]FBPG were analyzed
using the AMIDE and PMOD software. Semi-quantitative values,
tumor-to-muscle (T/M) ratio and standard uptake value (SUV), were
calculated and are depicted in Table 3. The T/M ratio for [18F]FPG
peaks at the beginning of the acquisition and declines over time. [18F]
FBPG has a tumor-to-muscle ratio close to one during the entire acqui-
sition period (Fig. 5).
Fig. 2. Concentration dependent uptake of [3H]glutamine in F98 cell line (top row) and PC-3 cell line (bottom row). Top left and bottom left graphs represent baseline uptake of [3H]
glutamine. The middle graphs represent uptake in presence of FPG. Top and bottom right graphs show the uptake of [3H]glutamine in the presence of FBPG.
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The results of the biodistribution of radiotracers [18F]FPG and [18F]
FBPG are shown in Table 5. Uptake of [18F]FPG in tumor tissue is seen
with a %ID/g value of 5.88 ± 1.02 20 min post-injection. A high uptake
in the liver (10.67 ± 3.03%ID/g) and kidneys (17.08 ± 6.08%ID/g) is
seen 20min post-injection, however after 60min the radioactivitymea-
sured in the liver (4.14 ± 1.08%ID/g) and kidneys (4.66 ± 3.60%ID/g)
has dropped steeply. A rapid clearance of the radiotracer out of the
bloodpool is seen with a circulation of 6.79 ± 1.53%ID/g after 20 min
which decreases to 2.56 ± 0.16%ID/g after 60 min. In the bladder, a
very high uptake is seen both 20 min (36.90 ± 35.72%ID/g) and
60 min (30.98 ± 16.37%ID/g) post-injection.
For [18F]FBPG, a neglectable tumor uptake of 0.46± 0.09%ID/g is ob-
served 20 min post-injection. Liver and kidneys display a value of
7.43 ± 1.80%ID/g and 11.52 ± 3.91%ID/g 20 min p.i. and 4.44 ± 0.83%Table 2
Inhibition of [3H]-labelled amino acid uptake by [19F]FPG and [19F]FBPG. The data repre-
sented in this table are the relative uptake of the amino acids in presence of the inhibitors
compared to basal uptake in absence of the inhibitors (n = 3).
Tracer/amino acid [3H]-L-glutamine [3H]-L-glutamic acid [3H]-L-serine
[19F]FPG 94 ± 9% 101 ± 13% 93 ± 1%
[19F]FBPG 92 ± 1% 110 ± 13% 95 ± 2%
Table 3
Inhibition of [3H]glutamine uptake by FPG and FBPG in the wild-type HEK-293 cell line
and the ASCT-2 knock-out HEK-293 cell line. The data represented in this table are the rel-
ative uptake of [3H]glutamine inpresenceof the inhibitors compared tobasal uptake in ab-
sence of the inhibitors. Each experiment was executed in triplicate (n = 3).
Cell line FPG FBPG
Wild-type HEK-293 96 ± 7% 95 ± 6%
ASCT-2 KO HEK-293 60 ± 7% 58 ± 9%ID/g and 14.46%ID/g after 60 min. Measured radioactivity in the blood
is 5.49 ± 0.74%ID/g 20 min p.i. and 4.24 ± 0.85%ID/g 60 min post-
injection. [18F]FBPG presence in the small intestine increases from
5.77 ± 5.82%ID/g 20 min p.i. to 19.10 ± 4.83%ID/g 60 min post-
injection.
4. Discussion
The metabolic importance of glutamine in tumor biology raised the
overall interest for amino acid derivatives asmolecular probes. Research
has led to the development of both therapeutic and diagnostic com-
pounds targeting their transporters and metabolic enzymes [28–31].
Due to the drawbacks of [18F]FDG and the “glutamine addiction” of sev-
eral tumors, different PET radiotracers based on the glutaminebackbone
have been developed [5–8,10–13,16,17]. In this study, we developed
and characterized [18F]fluorophenylglutamine ([18F]FPG) and [18F]
fluorobiphenylglutamine ([18F]FBPG), two novel fluorine-18 labelled
glutamine derivatives. Synthesis of the reference products and the pre-
cursors were successful. A satisfying yield (± 75%) was obtained for the
synthesis of the cold reference products while only amoderate yield (±
58%) was found for the precursor synthesis. The introduction of unpro-
tected hydroxyl groups, necessary for radiolabeling, results in a reduc-
tion of the synthesis yield. Masking the hydroxyl group (with a tert-
butyldimethylsilyl-group) could possibly increase the yields of the
amide formation. Deprotection of the amine and carboxylic acid with
aqueous HCl led to impurities. We hypothesize that hydrolysis of theTable 4
Semi-quantitative analysis of [18F]FPG and [18F]FBPG uptake in the PC-3 xenograft. For
both radiotracers, the mean tumor-to-muscle and mean standardized uptake value were
calculated.
FPG FBPG
T/Mmean 1.68 ± 0.24 1.20 ± 0.15
SUVmean 0.53 ± 0.25 0.17 ± 0.04
Fig. 3. μPET images (A and C) andCT images (B andD) of the PC-3 bearingmouse xenografts, tumors are delineatedwith awhite line. [18F]FPG has amoderate uptake in the tumors in both
flanks (A), [18F]FBPG has only limited uptake (C) in both tumors.
Fig. 4. μPET images (A and C) and contrast-enhanced T1-weightedMR images (B andD) of F98 bearing rat brain (outerwhite circle). Macroscopical tumor growth (delineated by the inner
white circle) was confirmed on the MRI images. Although both radiotracers enter the rat brain, no increased uptake in the tumor tissue was observed.
Table 5
Tissue uptake of [18F]FPG and [18F]FBPG in various organs and the blood of Swiss nu/nu
male mice at 20- and 60-min post-injection. Values are expressed as % ID/g of tissue ±
SD (n = 3).
Organ [18F]FPG [18F]FBPG
%ID/g 20 min %ID/g 60 min %ID/g 20 min %ID/g 60 min
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groups with 4MHCl in dioxane resulted in pure products, that could be
used without any further purification.
To obtain the fluorinated glutamine based PET tracers we firstly
attempted to displace a nitro-group with fluoride-18 for the develop-
ment of [18F]FBPG. However, due to the electrochemical properties of
the compound thedirect aromatic labellingwasnot feasible. Directfluo-
rination of the nitro moiety is possible, but requires harsh labelling con-
ditions [33]. In addition, the electrochemical properties are very
important for direct aromatic labelling, this can be seen in the dramatic
changes of labelling yields of [18F]MPPF depending on the position ofFig. 5. Evolution of the mean tumor-to-muscle ratio in function of the time for [18F]FPG
(blue) and [18F]FBPG (red) in the PC-3 animal model. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of
this article.)the electron withdrawing groups [34]. In neither [18F]FPG nor [18F]
FBPG, electron withdrawing groups are present. Moreover, the amide
and phenyl group were orientated para relative to the fluorine function
as electron donating groups, further complicating the possibility forpost-injection post-injection post-injection post-injection
Blood 6.79 ± 1.53 2.56 ± 0.16 5.49 ± 0.74 4.24 ± 0.85
Tumor 5.88 ± 1.02 2.22 ± 0.38 0.46 ± 0.09 0.42 ± 0.09
Muscle 1.48 ± 0.07 1.72 ± 1.16 0.45 ± 0.09 0.48 ± 0.28
Brain 2.96 ± 0.88 1.35 ± 0.13 0.67 ± 0.13 0.38 ± 0.03
Skin 1.92 ± 0.27 1.85 ± 0.95 0.79 ± 0.10 0.57 ± 0.10
Fat 1.77 ± 0.10 1.02 ± 0.16 0.92 ± 0.26 1.21 ± 1.05
Liver 10.67 ± 3.03 4.14 ± 1.08 7.43 ± 1.80 4.44 ± 0.83
Spleen 4.60 ± 0.69 1.61 ± 0.11 3.11 ± 0.28 2.07 ± 0.26
Lung 5.54 ± 0.95 2.17 ± 0.14 5.03 ± 1.14 3.75 ± 0.43
Kidney 17.08 ± 6.08 4.66 ± 3.60 11.52 ± 3.91 14.46 ± 1.71
Stomach 3.57 ± 2.97 1.57 ± 0.35 2.89 ± 1.72 0.85 ± 0.01
Small intestine 6.20 ± 1.04 7.37 ± 2.75 5.77 ± 5.82
19.10
± 4.83
Large intestine 4.23 ± 3.02 1.08 ± 0.12 0.39 ± 0.14
0.53
± 0.07
Bladder 36.90 ± 35.72 30.98 ± 16.37 1.33 ± 0.77 2.54 ± 1.47
Bone 3.94 ± 2.13 2.39 ± 0.15 0.95 ± 0.20 0.67 ± 0.14
Heart 5.45 ± 0.80 11.13 ± 15.81 2.03 ± 0.47 1.50 ± 0.52
Prostate 11.67 ± 1.54 13.66 ± 6.84 2.13 ± 1.90 2.60 ± 1.12
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alized precursor with the aid of the ruthenium complex was attempted.
The ruthenium complex withdraws enough electron density from the
phenol group through η6 π-coordination enabling labelling with
fluoride-18 via a Meisenheimer complex even in the presence of elec-
tron donating groups.
LogD7.4 values of−0.70 and 1.11 were measured for [18F]FPG and
[18F]FBPG, respectively. These values are much higher than the−3.64
logD7.4 value reported for glutamine [35]. This is explained by the intro-
duction of the lipophilic side-chain to the glutamine. The implementa-
tion of a fluorophenyl group increased the lipophilicity with a
hundredfold for [18F]FPG, the addition of a second phenylgroup in
[18F]FBPG resulted in another thirtyfold increase. The inhibition con-
stants were determined using concentration dependency experiments.
A limitation of this study is the lack of confirmation of the inhibitor con-
stants determined by cell uptake study using [18F]FPG and [18F]FBPG. In
these concentration dependency assays, differences in affinity of both
tracers towards the human PC-3 cells (Ki FPG = 234 μM; Ki FBPG =
604 μM) and rat F98 cells (Ki FPG = 850 μM; Ki FBPG = 1421 μM)
were observed. A possible explanation could be a difference in confor-
mational structure between rat and human ASCT-2 at the binding do-
main. This is supported by the low identity degree (14% as opposed to
the 79% sequence identity) of both transporters and the previously re-
ported difference in binding towards rat and human ASCT-2 of the 2-
amino-4-bis(aryloxybenzyl)aminobutanoic acids (N50-fold difference)
[36,37]. An alternative explanation can be found in the ASCT-2 expres-
sion of the two cell lines. PC-3 and F98 have a different expression
level of the transporter. This can possibly lead to a different measured
affinity of the two inhibitors. The difference in inhibition of glutamine
uptake in rat andhuman cellswas confirmed by the in vivo experiments.
With [18F]FPG, both tumors in the PC-3mousemodel were clearly visu-
alized, whereas no tumor uptake was seen on PET images in the F98 rat
model. In contrast to [18F]FPG, the discrepancy is not that clear with
[18F]FBPG, where tumor delineation is not feasible in both tumor
xenografts.
The results of the biodistribution study are in accordance to the PET
images. Uptake of [18F]FPG in tumor tissue is enhanced whereas the
tumor uptake of [18F]FBPG is neglectable. Both tracers give an elevated
signal in organs responsible for metabolization and elimination (e.g.,
liver, kidneys, intestines). [18F]FPG shows a high uptake in the liver
(10.67 ± 3.03%ID/g) after 20 min which decreases very rapidly to
4.14 ± 1.08%ID/g after 60 min. These results suggest a fast initial
metabolization of the tracer. The signal in the bladder which is much
higher than signal in the intestines points in the direction of predomi-
nant renal clearance of the radiotracer. In contrast to this, the clearance
of [18F]FBPG seems to be hepatobiliary or a combination of renal and
hepatobiliary clearance. The high uptake in the liver (7.43 ± 1.80%ID/
g 20min p.i.) in combination with the increased activity in the small in-
testine after 60 min (19.10 ± 4.83%ID/g) suggests an initial
metabolization combinedwith hepatobiliary clearance. The high uptake
in the kidneys (11.52± 3.91%ID/g 20min p.i.) indicates at least a partial
renal clearance. No enhanced uptake in the bone was seen for [18F]FPG
or [18F]FBPG. Therefore, no indication for defluorination was found and
metabolization of both radiotracers must occur via another, unknown,
metabolization pathway.
Because the μPET images with [18F]FPG provide a clear visualization
of the tumor, we believe that this tracer is a good lead for the develop-
ment of a radiotracer with high uptake in tumor tissue in vivo. Further
increasing the affinity of the imaging probe towards ASCT-2 would be
beneficial for visualizing malignancies. Work by Esslinger et al. empha-
sized the influence of arene substitutions on the binding properties [22].
Exploring a range of substitutions on the aromatic ring could provide
more insight into the exact configuration of the lipophilic pocket de-
scribed by several authors [22–24]. In this work, we developed a biphe-
nyl analogue to exploit the lipophilic pocket and thereby increasing the
affinity. However, the introduction of the second aromatic ring had adetrimental effect on the binding towards the ASCT-2 transporter.
Therefore, we believe that the lipophilic pocket is limited in size and
by introducing a second ring, the probe gets pushed out of the binding
site, explaining the loss of affinity. Future work should focus on explor-
ing the substitutions of the arene group. As such, increased affinities can
be obtained which should result in higher in vivo uptake in the tumor
tissue.
5. Conclusion
We investigated the imaging potential of two novel PET radiotracers
[18F]FPG and [18F]FBPG. The direct aromatic fluorination with fluoride-
18 was successful using a ruthenium-based method, subsequent
deprotection leads to the desired radiotracers. In vitro inhibition exper-
iments showed a moderate and low affinity of fluorophenylglutamine
and fluorobiphenylglutamine, respectively, towards the human ASCT-
2 transporter. Both compounds had a low affinity towards the rat
ASCT-2 transporter. These results were endorsed by the in vivo experi-
ments with low uptake of both tracers in the F98 rat xenograft, low up-
take of [18F]FBPG in the mice PC-3 xenograft and a moderate uptake of
[18F]FPG in the PC-3 tumors.We hypothesize that increasing the affinity
of [18F]FPG by optimizing the substituents of the arene ring can result in











LAT-1 L-type amino acid transporter
MET (S-methyl)-L-methionine
MRI magnetic resonance imaging
PET Positron emission tomography
SUV standardized uptake value
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